Articles | Volume 11, issue 4
https://doi.org/10.5194/jbji-11-395-2026
https://doi.org/10.5194/jbji-11-395-2026
Case report
 | 
06 Jul 2026
Case report |  | 06 Jul 2026

Literature review and case report on the use of rezafungin for spondylodiscitis in an outpatient parenteral antimicrobial therapy (OPAT) setting

Alexander J. Richards, Ammara Asif, Monica Ivan, Patrick J. Lillie, Gavin Barlow, and Chloe Walsh
Metrics will be available soon.
Latest update: 07 Jul 2026
Download
Short summary
Fungal infection can be difficult to treat, requiring long periods of hospitalisation. Rezafungin is a promising new antifungal medication that can be used to treat complex, deep-seated fungal infection. We examine the reported use of rezafungin in managing fungal infection of the bones and joints in an outpatient setting. Our case helps to provide further experience in the use of rezafungin as a powerful tool in helping patients get out of hospital and avoid further admissions.
Share